Abstract: Provided are compounds and a process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate (I) and uses thereof.

Abstract: The present invention discloses a new process for the preparation of 1,4-benzoquiones of formula (II) wherein R1, R2, R3 and R4 are independently selected from the group consisting of branched or unbranched C1-C6 alkyl, phenyl and benzyl, wherein phenyl and benzyl is optionally substituted by one or more substituent independently selected from the group consisting of C1-C6 alkyl and halogen, and wherein C1-C6 alkyl is optionally substituted with one or more halogen susbstituents, and wherein R2 and R3 together can form a C1-C6-alkylene radical, optionally substituted by one or more susbstituents independently selected from the group comprising C1-C6, benzyl, phenyl and halogen. One preferred compound is 2,3-dimethoxy-5-methyl-[1,4]benzoquinone, also known as coenzyme Q0 (CoQ0). Also disclosed are novel compounds and intermediates, and a method for the preparation of coenzyme Qn, preferable the coenzyme Q10.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present compound represented by formula(I) CH2?CR1—COO—(L)k-E1-E2-E3-(E4)m-(E5)n-R2??(1) provided that the symbols in the formula have the following meanings: R1: a hydrogen atom or a methyl group; R2: a C1-8 alkyl group; L: —(CH2)pO—, —(CH2)q—, -Cy-COO— (Cy is a trans-1,4-cyclohexylene group), -Cy-OCO—, -E6-(CH2)2—, -E7-CH2O— or -E8-O— (wherein each of p and q which are independent of each other, is an integer of from 2 to 8); E1, E2, E3 E4, E5, E6, E7, E8: each independently a 1,4-pheneylene group or a trans-1,4-cyclohexylene group (provided that at least one of E1, E2 and E3 is a trans-1,4-cyclohexylene group, and in a case where L is -Cy-OCO—, E1 is a trans-1,4-cyclohexylene group),and k, m, n: each independently 0 or 1, provided that when k is 1 and L is -Cy-COO—, -Cy-OCO—, -E6-(CH2)2—, -E7-CH2O— or -E8-O—, at least one of m and n is 0. The present compound is useful for liquid crystal composition and optical element.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The invention relates to novel compounds of the formula I, II; III or IV wherein the general symbols are as defined in claim 1. These compounds are useful as surface modifiers for polymers in order to improve resistance to fog formation or water and oil repellency.

Abstract: The present invention discloses the composition of antioxidant of bamboo leaves (AOB) and its use. The purpose of present invention is to provide a new food additive which is natural, nutritional, and muti-functional, and which is of rich resources, safety, good effect, and low cost. AOB is yellow or brown powders or particles obtained from bamboo leaves, wherein the main antioxidative components include flavones, lactones, phenolic acids. AOB can either inhibit lipid autoxidation chain reaction, or chelate transitional metal ions, and can be used as primary and second antioxidant. AOB can eliminate nitrite and inhibit the synthesis of N-nitrosamine, and has anti-bacteria, bacteriostatic, deodorizing, aroma enhancing etc. functions. AOB can be commonly used in oil-containing food, meat product, fishery product, expanded food etc. food systems.

Abstract: The invention provides a method for producing a PC copolymer having a specific structure from a diester diol serving as a starting material, which method attains enhanced productivity. The method for producing a polycarbonate copolymer through interfacial polymerization, the copolymer having structural repeating units represented by formulas (I) and (II), wherein a phenol-modified diol having a hydroxybenzoic acid content of 500 ppm by mass or less is employed as a starting material. In formulas (I) and (II), each of R1 and R2 represents a C1 to C6 alkyl group; X represents a single bond, a C1 to C8 alkylene group, a C2 to C8 alkylidene group, a C5 to C15 cycloalkylene group, a C5 to C15 cycloalkylidene group, —S—, —SO—, —SO2—, —O—, —CO—, etc. Each of R3 and R4 represents a C1 to C3 alkyl group; Y represents a C2 to C15 linear-chain or branched alkylene group; a to d are integers of 0 to 4; and n is an integer of 2 to 450.

Abstract: The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

Abstract: Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

Abstract: Novel derivatives of fumagalone have the general formula (I): and are useful angiogenes is inhibitors; these can be formulated into pharmaceutical compositions suited for human or veterinary medicine, or can be formulated into cosmetic compositions.

Abstract: The present invention provides novel intermediates represented by general formula (I) etc. for preparing a phenoxyacetic acid derivative represented by general formula (X) or a pharmaceutically acceptable salt thereof, which has ?3-adrenoceptor stimulating activity and are useful for treating or preventing obesity, hyperglycemia, diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression or biliary calculus.

Abstract: Compounds having a formula: or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders.

Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Abstract: The present invention provides novel intermediates represented by general formula (I) etc. for preparing a phenoxyacetic acid derivative represented by general formula (X) or a pharmaceutically acceptable salt thereof, which has ?3-adrenoceptor stimulating activity and are useful for treating or preventing obesity, hyperglycemia, diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression or biliary calculus. The present invention also provides a process for preparing said intermediates and a method of using said intermediates.

Abstract: A method for preparing a prostaglandin F-type compound. Also disclosed is an intermediate of the following formula (II) compound wherein R?, X and A have the same meaning as given in the specification.

Abstract: This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.

Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: A process for producing optically pure R-hydroxyphenoxypropanoic acid or a salt or ester thereof by reaction of hydroquinone or a salt thereof with an S-halopropanoic acid or a salt thereof in the presence of a mild reducing agent.

Abstract: Formula (I) compounds are described, where the groups are defined in the description, as well as processes for their preparation and their use as medicaments, particularly as selective phosphodiesterase IV inhibitors.

Abstract: A retardation plate having a high film strength and having an optical property is provided by using a biaxial liquid crystal compound, in which the direction having a minimum refractive index of the optically anisotropic thin layer almost coincides with the normal direction in the film plane of the retardation plate, and the retardation plate comprises a transparent support and at least one optically anisotropic layer containing a liquid crystal compound capable of expressing a biaxial liquid crystal phase, wherein the liquid crystal compound is a polymerizable compound and/or a polymer compound.

Abstract: Novel compounds of the general formula (I), wherein Ar, R1, R2, X1, X2, Y1, Y, and Z are as defined in the specification, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype.

Abstract: There is disclosed a liquid crystalline polyacetylene having a repeat structure of the formula where spa is a spacer group and mes is a mesogenic substituent.

Abstract: The invention provides a process for preparing a compound useful for inducing or maintaining general anesthesia or sedation in mammals.

Abstract: A new chromotropic compound, compositions containing such a compound and methods of using such compound, such as in a test method for identifying the presence of free radicals, are disclosed.

Abstract: A compound is of formula (I), in which: A1 to A4, E1 and E2 each independently represent hydrogen or an optionally-substituted hydrocarbon group; B1 and B2 each independently represent a single bond, an oxygen atom or an optionally-substituted hydrocarbon group; MG1 and MG2 each independently represent an optionally-substituted ring system; CG is a divalent or polyvalent chiral group. The optically active compound may be used as a doping agent for liquid crystals for a wide range of applications including solid state cholesteric filters for projection displays, circular polarisers, optical filters, etc.

Abstract: A process for the preparation of fibrates of formula I in which R1 is a halogen atom, a 2,2-dichloro-cyclopropyl group, a (4-chlorophenyul)-hydroxymethyl group, a-4-chlorobenzoyl group or a 2-(4-chlorobenzamido)-ethyl group, and R2 is hydrogen or a C1-C4 alkyl group.

Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? suptype.

Abstract: The present invention relates to the compounds of the general formula (I) and their salts and stereoisomers for the production of medicaments for the treatment of cardiovascular disorders.

Abstract: Trifluoromethyl-substituted spirocyclic ketoenols of the formula (I) are provided wherein Het represents one of the groups and G, V, W, X, Y, and Z are as defined in the specification. Also provides are processes for the preparation of the compounds. The compounds of formula (I) find use as pesticides.

Abstract: The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(?)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.

Abstract: A compound of formula I wherein A is a moiety which provides UV absorbing activity to the compound of formula I that comprises 1 divalent group or 2 monovalent groups, with at least one group having carbonyl (C═O) functionality. R6 is linear or branched C1-C8 alkyl and R5 is a linear or branched C1-C8 alkyl or hydrogen. Sunscreen formulations which contain these compounds and methods for using these compounds to prepare formulations are also provided.

Abstract: A process is described for the stereospecific preparation of an ester of formula (I): wherein * signifies the (R) stereoisomer; R1 is selected from C1-6 alkyl, preferably ethyl; and R2 is hydrogen, a protecting group or a leaving group which process comprises reaction of a nitrile of formula (II): wherein * signifies the (R) stereoisonomer; and Ph is the phenyl group C6 H5 with a solution of an inorganic acid in an alcohol and optional conversion of the compound of formula (I) wherein R2 is H so prepared to any other desired compound of formula (I) by standard methods in the art. The compounds of formula (I) are chiral esters, useful as intermediates in the synthesis of the family of acetylcholine esterase (ACE) inhibitors known as “prils”, such as lisinopril, cilazapril, enalapril, benazepril, ramipril, delapril, enalaprilat, imidapril, spirapril, trandolapril and others.

Abstract: The present invention provides a process for the preparation of homophthlate esters useful in the preparation of homophthalic anhydride reactants.

Abstract: In one embodiment, the invention relates to compounds of the formula (I) wherein G1 and G2 independently represent a polymerisable mesogenic residue, X and Sp are as defined herein and M represents an achiral group of formula (II) as defined herein. The compounds of the invention may, for example, be useful as curable liquid crystals and for preparing liquid crystal films.

Abstract: A process for the preparation of fibrates of formula I 1

Abstract: There are disclosed amphoteric nano-sized metal oxide particles functionalized with silyl esters of a phosphonate and composites thereof with an acrylate-based monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Also disclosed are the method making such functionalized particular by reacting a metal oxide with a silyl ester of a phosphonate in the presence of a non-aqueous solvent and in an inert atmosphere and the method of making the composites wherein the functionalized particles are admixed with an acrylate-based matrix monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Further disclosed is the method of dental repair wherein the composites are applied to a tooth and photopolymerized.

Abstract: The invention relates to compound of formula (I): 1

Abstract: In one embodiment, the invention relates to compounds of the formula (I) wherein G1 and G2 independently represent a polymerizable mesogenic residue, and X, Sp, and Q are as defined herein. The compounds of the invention may, for example, be useful as curable liquid crystals and for preparing liquid crystal films.

Abstract: Compounds of formula (I) may be used as alignment layers in liquid crystal devices wherein X1-5 are idependently selected from H, F, CN, phenylene, C1-10 alkyl, whereby when X1=X2, then X1,2=H and when X3=X4, then X3,4=H, S1-3 are spacer units, PG1-3 are photoisomerisable/dimerisable groups.

Abstract: The invention relates to a process for the preparation of hydroxybenzoic benzyl esters by reacting dibenzyl ethers with alkylcarbonyloxybenzoic or alkoxycarbonyloxybenzoic acids and optionally anhydrides thereof in the presence of one or more acids as catalyst.

Abstract: Process for the esterification of organic acids with alcohols in a reactor of the chromatographic type in which the heterogeneous solid phase is capable of acting both as an esterification catalyst and as a means exhibiting preferential adsorption towards one of the reaction products (typically water). The process to which the present invention relates is particularly improved compared with conventional technology owing to the use, as the means for regenerating the catalyst, of a desorbent to which has been added a second compound, generally the anhydride of the acid used in the esterification reaction, which, by chemical reaction, completes the removal of the adsorbed water.

Abstract: Provided is a bis(diphenylvinyl)arene compound having a reactive functional group on phenyl group, represented by below formula (1), 1

Abstract: The present invention relates to an improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1) useful as an intermediate for the preparation of many pharmaceutically active compounds.

Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.

Abstract: The invention provides LC compositions that exhibit V-shaped switching when aligned in an analog device configuration and exhibit bistability when aligned in a bookshelf-type device configuration. The invention more specifically provides LC compositions of formula 1 and particularly chiral nonracemic compounds of formula 1 which exhibit bistable switching as well as V-shaped switching when aligned in appropriate device configurations. The invention also provides methods of using the compounds of the invention in making LC compositions and electooptical devices comprising an aligned layer of the compositions of this invention.

Abstract: A fungicidal compound of formula (I) having a fluorovinyloxyphenyl moiety and stereoisomers thereof are useful for protecting crops from fungal diseases: wherein: X is CH or N; Y is O or S; Z is O or NH; R1 is hydrogen or CF3; and R2 is hydrogen, a C1-10 alkyl, naphthyl, thiophenyl or a phenyl group optionally carrying one or more substituents selected from the group consisting of C1-6 alkyl, halogen-substituted C1-6 alkyl, C1-6 alkoxy, phenoxy, halogen, and methylenedioxy radicals.

Abstract: There are disclosed amphoteric nano-sized metal oxide particles functionalized with silyl esters of a phosphonate and composites thereof with an acrylate-based monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Also disclosed are the method making such functionalized particular by reacting a metal oxide with a silyl ester of a phosphonate in the presence of a non-aqueous solvent and in an inert atmosphere and the method of making the composites wherein the functionalized particles are admixed with an acrylate-based matrix monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Further disclosed is the method of dental repair wherein the composites are applied to a tooth and photopolymerized.

Abstract: A compound selected from the group consisting of a compound of the formula wherein the substituents are defined as set forth in the specification and its salts with non-toxic pharmaceutically acceptable acids and bases useful for treating loss of bone matrix.

Abstract: Phenoxyacetic acid derivatives of the formula: wherein R1, R2, Xn and A are as defined herein, and a process for preparing the derivatives. The derivatives are used as herbicides.